Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?—a literature review

The advent of immune-checkpoint inhibitors (ICIs) targeting the programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) axis, produced a paradigm change of the treatment algorithm for metastatic, non-oncogene addicted, non-small cell lung cancer (NSCLC). However, the majority of patients with on...

Descripción completa

Detalles Bibliográficos
Autores principales: Leone, Gianmarco, Passiglia, Francesco, Bironzo, Paolo, Bertaglia, Valentina, Novello, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Review Article on Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815346/
https://www.ncbi.nlm.nih.gov/pubmed/33489826
http://dx.doi.org/10.21037/tlcr-20-710

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815346/
https://www.ncbi.nlm.nih.gov/pubmed/33489826
http://dx.doi.org/10.21037/tlcr-20-710

Ejemplares similares